Safety and Efficacy Trial of MTX101 2mg for the Acute Treatment of Migraine in Adults
Completed · Phase 2 · Has a placebo group
Conditions studied: Migraine
In brief
The goal of this clinical trial is to learn if drug MTX101 works to treat acute migraine attacks in adults. It will also learn about the safety of the drug MTX101. The main questions it aims to answer are: Does the drug MTX101 lower headache pain for participants and the need to use a rescue medication? What side effects, if any, do participants have when taking the drug MTX101? Researchers will compare the drug MTX101 to a placebo (a look-alike substance that contains no drug) to see if the drug MTX101 works to treat acute migraine attacks. Participants will: Take the drug MTX101 or a placebo to treat 1 migraine attack with each treatment. Visit the clinic twice and have one phone call over a 4 week period for checkups and tests. Keep a diary of their symptoms and the number of times they use a rescue medication.
Key facts
- Study ID
- NCT06728553
- Run by
- Manistee Therapeutics
- People needed
- 78
- Starts
- 2025-02-24
- Expected to finish
- 2025-07-28
- Last updated by the study team
- 2025-10-07
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Kaizen Brain Center — La Jolla, California, United States
- Clinical Research Institute, LLC — Santa Monica, California, United States
- Brainstorm Research — Miami, Florida, United States
- Synergy Clinical Research/Emerald Coast Center for Neurological Disorders — Pensacola, Florida, United States
- DelRicht Research — New Orleans, Louisiana, United States
- QUEST Research Institute — Farmington Hills, Michigan, United States
- Wasatch Clinical Research — Salt Lake City, Utah, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.